Cytokinetics, Incorporated
CYTK
$60.06
$0.060.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.22% | -127.86% | 16.73% | -7.57% | 6.56% |
| Total Depreciation and Amortization | 6.79% | 17.24% | -0.65% | -3.48% | -1.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -77.31% | 215.62% | 68.27% | -19.06% | -13.68% |
| Change in Net Operating Assets | -108.19% | 144.08% | -882.34% | -112.47% | 322.04% |
| Cash from Operations | -32.69% | 16.17% | 2.57% | -100.73% | 35.40% |
| Capital Expenditure | 39.66% | -125.67% | 26.82% | -339.07% | -84.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.37% | -208.06% | -48.91% | -0.48% | 352.87% |
| Cash from Investing | -0.30% | -234.22% | -50.09% | -4.43% | 346.07% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 99.33% | -14,918.87% | 6.45% | 1.03% | -0.69% |
| Issuance of Common Stock | 111.22% | 2.82% | -11.84% | 18.07% | 2.55% |
| Repurchase of Common Stock | -69.58% | -40.08% | -3,853.85% | 98.90% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Financing | -66.50% | 320.80% | 1,551.94% | 99.41% | -30.39% |
| Foreign Exchange rate Adjustments | 315.22% | 106.74% | -152.59% | -192.47% | 331.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -167.72% | 5,990.87% | 111.79% | -144.15% | 133.49% |